항체 단편 시장 성장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Antibody Fragments Market was valued at USD 7.3 billion in 2023 and is anticipated to grow at 5.6% CAGR from 2024 to 2032. Antibody fragments are smaller components derived from full-length monoclonal antibodies. They are specifically designed to retain the binding specificity of their parent antibodies while offering unique properties that make them suitable for applications where whole antibodies may be less effective. One of the primary drivers of market growth is the increasing demand for targeted therapies. The rise of personalized medicine has led to a growing interest in biologic therapies that provide high specificity.

Antibody fragments are particularly well-suited for these targeted therapies, especially in oncology and immunology, due to their ability to be tailored for specific antigen interactions. The market can be categorized based on specificity, dividing it into monoclonal antibodies and polyclonal antibodies. The monoclonal antibody category includes various products tailored for specific therapeutic uses. In contrast, the polyclonal antibody segment features different products designed to address a range of health concerns.

The monoclonal antibody segment is projected to reach USD 7.5 billion by 2032, reflecting the ongoing innovation in this area. When analyzing the market by type, antibody fragments are further classified into FAB, scFv, sdAb, and other types. The single-chain variable fragment (scFv) segment alone accounted for USD 2.3 billion in 2023. The growing prevalence of cancer significantly contributes to the success of the scFv segment, as these fragments are increasingly used in targeted cancer therapies. Their smaller size enables them to access challenging targets, such as tumor cells located deep within tissues or in specific microenvironments that larger antibodies may not reach effectively.In the United States, the antibody fragments market is assumed to expand significantly, reaching USD 4 billion by 2032.

The region has one of the highest cancer rates globally, which drives the demand for innovative cancer therapies and, consequently, antibody fragments. Additionally, numerous leading biotechnology and pharmaceutical companies in the U.S. support the development and commercialization of these therapies, further propelling market growth. As the demand for personalized and targeted treatments continues to rise, the antibody fragments market is poised for significant advancements and expansion in the coming years.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising demand for targeted therapies
    • 3.2.1.2 Growing prevalence of cancer
    • 3.2.1.3 Advances in biotechnology and genetic engineering
    • 3.2.1.4 Growth in regulatory approvals
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Concerns related to stability in single-chain variable fragments
    • 3.2.2.2 High development cost
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 Pipeline analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Specificity, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Monoclonal antibody
  • 5.2.1 Praxbind (Idarucizumab)
  • 5.2.2 Ranibizumab (Lucentis)
  • 5.2.3 Certolizumab pegol (Cimzia)
  • 5.2.4 Iodine (I 311) metuximab/ licartin
  • 5.2.5 Beovu (Brolucizumab-dbll)
  • 5.2.6 Cablivi (Caplacizumab-yhdp)
  • 5.2.7 Blinatumomab
• 5.3 Polyclonal antibody
  • 5.3.1 Crofab
  • 5.3.2 Anavip
  • 5.3.3 Anascorp
  • 5.3.4 Botulism antitoxin heptavalent
  • 5.3.5 Digibind
  • 5.3.6 Digifab

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 FAB
• 6.3 scfv
• 6.4 sdab
• 6.5 Other types

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cancer
• 7.3 Immunodeficiency
• 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Amgen
• 9.3 AstraZeneca
• 9.4 BioNTech
• 9.5 Bristol-Myers Squibb Company
• 9.6 Eli Lilly and Company
• 9.7 Genentech, Inc.
• 9.8 Johnson & Johnson
• 9.9 Merck & Co.
• 9.10 MorphoSys
• 9.11 Novartis AG
• 9.12 Pfizer Inc.
• 9.13 Sanofi
• 9.14 Takeda Pharmaceutical Company Limited
• 9.15 UCB Pharma